JAMES DE REGIS

Hospital & Office Representative in Delaware and Eastern Shore, MD. Responsible for the promotion of Farxiga, Brilinta, and Andexxa to Cardiologists, Heart Failure Clinics, Cath Labs, and Pharmacy.

• 2024 Secured market share leadership and volume growth with key cardiologists. Resolve authorized generic and EPIC issues. One of district leaders in priority omni-channel customer engagements. CBD mentorship for leadership role. Onboarding new territory partner. Successful National Broadcast Event with key customers. Collaborate with acute care colleague and MSL's to connect with key cardiologists. ACC, ACP, DSHP exhibits.
• 2023 One of three national CV representatives selected for LEAP Cohort 22. NE Regional FIeld Based Trainer. One of "Summer Sizzle" national contest winners for MS growth. Developed & implemented "Powerful Persuasion Podcast" for NE Region. Created DELIVER launch tools for National Launch Meeting. Andexxa district champion. UMMS Program with AstraZeneca CV Medical Director and key customers. Developed and coordinated AZ leadership dinner with DE ACC/ACP chapters. Selected by NFBT/Brand to participate in "Farxiga Accelerate Now Initiative". Selected by leadership to participate in AHA Philadelphia. Ranked 102 of 162.
• 2022 Selected as Regional Field Based Trainer for NE region. Participate in leadership meetings and oversee a team of DTS's. Selected for AZ Headquarter Preceptorship Program. Selected for COMEX new hire training. Completed AZ Project Agility/Omni-Channel training. Implemented key Beebe HF Transition of Care Team dinner program. High priority formulary work with all institutions. Ranked 115 of 173.
• 2021 Ranked 86 of 238. Interim DM while district manager on paternity leave. Participated in leadership calls. Brilinta commercial share regional leader for Q1 & Q2. One of the regional drivers for Farxiga trialists. Developed Christina Care HF Clinic without formulary win. Numerous CatAlyZe awards. Successful live fellow/customer dinner meetings with Regional Director. Awarded year end stock options.
• 2020 Started training in January and territory in March. No ranking due to COVID pandemic. Challenging and successful launch of Farxiga HFrEF indication during pandemic. Territory was one of regional leaders in trialists. Overcame challenges to get Farxiga to P&T for formulary review in several institutions. Successfully leveraged Veeva Engage virtual platform to connect with customers. Virtual speaker programs.

Responsible for the promotion of Xarelto to Cardiologists, Electrophysiologists, Hematologists, and Oncologists throughout Delaware. Janssen Pharmaceuticals / Johnson & Johnson premier IQVIA contract.

• 2019 Ranked 11 out of 102 through July. District Trainer. Interim District Manager when DM away. #1 NRx share and 2.5mg volume growth in Region. Recognized by leadership for achieving consistent top tier business results.
• 2018 Ranked 20 out of 102. District Trainer. Interim District Manager when DM away. Launch new indication & vascular dose for CAD/PAD patients. Support Invokana team with Cardiologists.
• 2017 President's Club- Ranked 10 out of 167. #1 rank in Philadelphia District. District Trainer. Team DE recognized by leadership for model of collaboration & achievement.
• 2016 Ranked 58 out of 250. First full year on territory.
• 2015 Hired in July and successfully completed Janssen training. Started territory in November.

Responsible for the launch and promotion of Ofirmev, Xartemis XR, Exalgo, Pennsaid, Sumavel DosePro, and Duexis to hospital & office based physicians throughout Delaware and Eastern Shore, MD. Unique opportunity to launch three products in the market place to over 200 physicians and 350 pharmacies. Specialty physicians include Pain Management Specialists, Orthopedic Surgeons, General Surgeons, Anesthesiologists, Rheumatologists, Oncologists, and Neurologists.

• 2015 Transitioned to Acute Care Surgical Specialist. Hospital & surgical account based selling of Ofirmev. Mid-year rank 38 of 150.
• 2014 Ranked 30 of 319. VP Advisory Board. Promoted to Senior Specialty Representative.
• 2013 Leadership Development Program. Managed Care Advisory Council. Ranked 63 of 211.
• 2012 Ranked 29 out of 238. Northeast Regional Representative of the Year. Voted MVP National Launch Meeting. #1 ranked New Jersey district team member. Duexis Field Advisory Committee and Exalgo Surge Team Representative.
• 2011 Ranked 59 of 243. Special Achievement Award Winner for customer focused strategy with Mid-Atlantic Spine and Pain Physicians. Exalgo Message Iteration Process Team and Representatives National Advisory Board.
• 2010 Ranked 77 out of 250. Designed comprehensive business strategy for multiple state geography to achieve successful launch of Exalgo and Pennsaid. Achieved 251% to plan for Pennsaid for first six months of product launch. Achieved over 200% growth for Exalgo and 125% growth for Pennsaid during second half of product launch from October through February.
• Identified and developed KOL's in territory to champion Mallinckrodt as a leader in pain management.
• Coordinated communication with senior management to achieve high-level customer focus
• Selected by manager to mentor other team members in effort to enhance selling skills and customer focus behaviors.

Responsible for the promotion of multiple products (Vioxx, Fosamax, Singulair, Vytorin, Zetia, Januvia, Janumet) to specialty & primary care physicians across a variety of therapeutic areas. Territories included DE, Southern NJ, Media & Mainline PA, and portions of Eastern Shore, MD. Specialty physicians called on include Cardiologists, Endocrinologists, Orthopedic Surgeons, Rheumatologists, Pain Management Specialists, Nephrologists, Pediatricians, and Obstetrics & Gynecology.

• 2009 Transitioned to Merck's new commercial model. Recognized by Senior Business Director for outstanding business planning & execution. Award of Excellence for outstanding contribution to building district morale and cohesiveness. High-level of team work and communication across the organization. Implemented new programs and behaviors designed to enhance customer trust and value.
• 2008 YTD TRx share change/power rank performance was strongest in the district and above nation. Recognized by Senior Business Director as one of three regional winners in the “Rise to the Challenge” incentive plan post market event. Award of Excellence for a demonstrating customer value and Merck Leadership principals.
• 2007 YTD share change/power rank was 32 out of 91 in the region and top-third in the nation. Promoted to Senior Specialty Representative. Awarded mid-year stock options for performance and future contributions critical to Merck's success. Award of Excellence for developing and implementing team building exercise. Selected by management to participate in Merck's Mentorship Program designed to develop and retain Merck's future leaders. Completed several courses designed to enhance sales and leadership skills.
• 2006 Director's Award winner achieving top 15% of the Nation. YTD PPO 105.4%, which ranked 37 of 179 in the nation. Championed creative team initiatives and was awarded District MVP as selected by my colleagues. Award of Excellence for presentation at 2S meeting.
• 2005 Director's Award winner at achieving top 25% of the Nation. YTD PPO and share change finished among the strongest performing reps in the nation. FACT share change incentive program winner.
• 2004 Started territory assignment in June. Product withdrawn from the market and transitioned to new product assignment in 2005.
• Liaison to territory thought leaders and speaker advocates within medical community.
• Team product point representative for Fosamax, Vytorin, and Zetia
• Successfully overcame the challenges of numerous product market events. Presence valued by many key customers that played a critical role in patient care and territory success during these periods.

Clinical Specialist in the Department of Cardiovascular-Merck Research Labs assigned to Project MK-0767 type-II diabetes & dyslipidemia. Responsible for the clinical monitoring of patients and staff for 34 investigational sites involved in Phase III testing.

• Advise and communicate daily with site physicians, nurses, and research staff regarding all project related questions and issues.
• Effectively monitor and manage patient clinical labs in addition to the medical review of patient data and adverse experiences. Responsible for the approval and monitoring of study drug allocation.
• Assist senior staff in authoring and revisions to protocols 034 & 035 and developing clinical study reports. Develop and implement recruitment strategies with team as well as manage site recruitment success.
• Provide in-service training to physicians and nurses during site visits, project investigator meetings, and via video/teleconference. Coordinate efforts with Department of Metabolism documentation specialist, financial specialist, and field MRAs to manage sites.

Co-investigator for 4-year National Institute of Health funded Department of Cardiology hypertension research project SHAPE. Project designed to study the effects of a 6-month exercise intervention on stage-I hypertension with subjects 55-75 years of age.

• Conduct and interpret patient cardiovascular and metabolic stress tests using solid knowledge of advanced ECG and PFT. Analyze MRI visceral and subcutaneous adipose abdominal images in addition to conducting and interpreting DEXA scans.
• Conduct muscular strength assessment and assist in echocardiogram vascular endothelial and stiffness functional testing. Design and conduct patient rehabilitation protocols and responsible for subject health status and progress during the intervention.
• Successfully recruit subjects by developing and implementing various strategies to accomplish project recruitment goals. Manage project data collection and databases, perform data analysis, and participate in cardiovascular and sports medicine professional meetings by presenting project abstracts.

• Taught freshman and sophomore courses each semester in the Department of Health Education in addition to my Director and graduate education responsibilities.

• Awarded competitive graduate assistantship in the Department of Exercise Science. Taught graduate lab sections and elective courses. Supervised, organized, and promoted department's Healthworks project.
• Selected for competitive graduate clinical internship at Crouse Irving Memorial Hospital offering rehabilitation experience with phase I, II, III, and IV patients. Conducted clinical patient evaluations, cardiac and metabolic stress testing, rehabilitation training, and patient education.
• Surgical observational experience includes coronary bypass, pacemaker, cardiac valve replacement, lung reduction, and carotid artery, in addition to observational experience in the catheterization lab, electrophysiology lab, echocardiogram, and nuclear stress testing.

• Reorganized and facilitated the development, implementation, and promotion of corporate health projects. Charged with managing and training a staff of ten responsible for the promotion and financial success of these projects.

• Developed, organized, and taught high school and junior high school health education curriculum for 225 students. Member of the public relations committee that developed and implemented community education projects.